Do we need new phosphate binders in dialysis?

Mario Cozzolino; Andrea Galassi; Paola Ciceri

doi:10.1093/ckj/sfaa246

Do we need new phosphate binders in dialysis?

Clin Kidney J. 2020 Dec 16;14(2):474-475. doi: 10.1093/ckj/sfaa246. eCollection 2021 Feb.

Authors

Mario Cozzolino¹, Andrea Galassi¹, Paola Ciceri²

Affiliations

¹ Renal Division, ASST Santi Paolo e Carlo, Depart. of Health Sciences, University of Milan, Milan, Italy.
² Renal Research Laboratory, Department of Nephrology, Dialysis and Renal Transplant, Fondazione Ca' Granda IRCCS, Ospedale Maggiore Policlinico, Milan, Italy.

Abstract

Patients affected by chronic kidney disease (CKD) have a greater risk of mortality than the general population. Fatal cardiovascular events are the most frequent cause of death in CKD patients, especially in the late stages of disease. Derangement of mineral metabolism and hyperphosphataemia are currently accepted as pivotal triggers of these vascular complications. Phosphate binders represent the common strategy to counteract hyperphosphataemia in dialysis patients. Several studies have reported a reduction in mortality risk in dialysis patients receiving phosphate binders compared with untreated patients, independent of the class of binder prescribed.

Keywords: CKD-MBD; dialysis; hyperphosphataemia; phosphate binder.

Publication types

Editorial